Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975387 · ClinicalTrials.gov registry record · Phase 1
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT03975387: Clinical Trial Phase 1 study, sponsored by Taiho Oncology.
NCT03975387 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 106 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03975387, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design. Sponsor made the strategic decision to not pursue the Phase 2 part of the study.
Interventions
- DRUG ASTX295
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 1 |
Why NCT03975387 stopped before completion
NCT03975387 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 1 intervention - of which ASTX295 is the first listed.
NCT03975387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03975387 about?
NCT03975387 is a clinical study titled "Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53". Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design. Sponsor made the strategic decision to not pur...
What is the current status of trial NCT03975387?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2019-07-11. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT03975387?
The interventions under investigation include: ASTX295 (DRUG).
Who is sponsoring clinical trial NCT03975387?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03975387's enrollment target sits among peer trials
106 531st of 2000 higher than 1,468 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI